| Literature DB >> 31571248 |
Renata R T Castro1,2,3, Emer Joyce4, Neal K Lakdawala1, Garrick Stewart1, Anju Nohria1, Michael M Givertz1, Akshay Desai1, Eldrin F Lewis1, Lynne W Stevenson5.
Abstract
BACKGROUND: Patient limitations guide selection of heart failure therapies, for which indications often specify New York Heart Association Class.Entities:
Keywords: cardiomyopathy; cardiovascular disease; heart failure
Mesh:
Year: 2019 PMID: 31571248 PMCID: PMC6906987 DOI: 10.1002/clc.23269
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882
Figure 1Patient's flow diagram. HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification
Patients demographics and clinical characteristics accordingly to NYHA functional classification
| All patients | NYHA I | NYHA II | NYHA III | NYHA IV |
| |
|---|---|---|---|---|---|---|
| Number of patients (%) | 948 (100.0) | 376 (40) | 343 (36) | 216 (23) | 12 (1) | |
|
| ||||||
| Age (years) | 57 ± 16 | 52 ± 16 | 58 ± 15 | 61 ± 15 | 62 ± 10 | <.001 |
| BMI (kg/m2) | 30 ± 7 | 29 ± 6 | 30 ± 6 | 31 ± 8 | 30 ± 11 | <.001 |
| Female, n (%) | 379 (40) | 141 (37) | 143 (42) | 90 (42) | 5 (42) | .65 |
| LVEF (%) | 42 ± 16 | 46 ± 15 | 40 ± 16 | 39 ± 18 | 39 ± 17 | <.001 |
|
| ||||||
| Diabetes mellitus (%) | 210 (22) | 48 (13) | 89 (26) | 66 (31) | 7 (58) | <.001 |
| Obstructive lung disease (%) | 149 (16) | 32 (8) | 60 (17) | 50 (23) | 7 (58) | <.001 |
| Chronic kidney disease (%) | 133 (14) | 25 (7) | 58 (17) | 45 (21) | 5 (42) | <.001 |
| ICM (%) | 156 (16) | 34 (9) | 79 (23) | 41 (19) | 1 (8) | <.001 |
| Hypertension (%) | 432 (46) | 139 (37) | 160 (47) | 124 (57) | 8 (67) | .003 |
| Atrial fibrillation/flutter (%) | 260 (26) | 65 (17) | 100 (29) | 79 (37) | 5 (42) | <.001 |
|
| ||||||
| ICD (%) | 244 (39) | 77 (31) | 105 (44) | 59 (44) | 2 (20) | .012 |
| CRTD (%) | 95 (20) | 17 (10) | 41 (22) | 34 (31) | 3 (30) | <.001 |
| ACE inhibitors/ARBs (%) | 678 (72) | 263 (70) | 253 (74) | 153 (71) | 9 (75) | .70 |
| Beta‐blockers (%) | 753 (79) | 276 (73) | 289 (84) | 177 (82) | 11 (92) | .002 |
| Diuretic agents (%) | 544 (57) | 141 (37) | 220 (64) | 172 (80) | 11 (92) | <.001 |
| Digoxin (%) | 216 (23) | 56 (15) | 80 (23) | 75 (35) | 5 (42) | <.001 |
| Warfarin (%) | 307 (32) | 85 (23) | 122 (36) | 93 (43) | 7 (58) | <.001 |
| Amiodarone (%) | 102 (11) | 29 (8) | 48 (14) | 22 (10) | 3 (25) | .019 |
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; LVEF, left ventricle ejection fraction; ICD, implantable cardioverter defibrillator; ICM, ischemic cardiomyopathy.
*P < .05 vs all other groups; **P < .05 vs NYHA I; ***P < .05 vs NYHA II.
Figure 2Degree of limitations to perform daily activities reported by ambulatory heart failure patients. Panel A includes all patients (NYHA I to IV; n = 948) and panels B, C, and D include patients designated as NYHA class I (n = 376), II (n = 343), and III (n = 216), respectively. Colors indicate the perceived degree of limitation for each activity
Patients demographics and comorbidities accordingly to left ventricular ejection fraction subtype
| HFrEF | HFbEF | HFpEF |
| |
|---|---|---|---|---|
| Number of patients (%) | 400 (42) | 382 (40) | 166 (18) | |
|
| ||||
| Age (years) | 52 ± 14 | 54 ± 16 | 64 ± 16 | <.001 |
| BMI (kg/m2) | 29 ± 7 | 30 ± 7 | 30 ± 8 | .34 |
| Female, n (%) | 111 (28) | 175 (46) | 93 (56) | .65 |
| LVEF (%) | 26 ± 7 | 52 ± 8 | 60 ± 7 | <.001 |
|
| ||||
| Diabetes mellitus (%) | 100 (25) | 58 (15) | 52 (31) | <.001 |
| Obstructive lung disease (%) | 57 (14) | 57 (15) | 35 (21) | .11 |
| Chronic kidney disease (%) | 67 (17) | 33 (9) | 33 (20) | <.001 |
| ICM (%) | 102 (25) | 54 (14) | 0 (00) | <.001 |
| Hypertension (%) | 166 (42) | 163 (43) | 103 (62) | <.001 |
| History of atrial fibrillation/flutter (%) | 112 (28) | 85 (22) | 53 (32) | .038 |
Abbreviations: BMI: body mass index; ICM: ischemic cardiomyopathy; HFbEF: Heart failure with better ejection fraction; HFpEF: Heart failure with reduced ejection fraction; HFrEF: Heart failure with reduced ejection fraction; LVEF: left ventricle ejection fraction.
*P < .05 vs all other groups; **P < .05 vs HFrEF; ***P < .05 vs HFpEF.
Figure 3Percentage of patients reporting limitations to perform daily life activities accordingly to left ventricular ejection fraction subtype. *P < .01 vs HFpEF & HFrEF. P values from multivariate logistic regression adjusted by age, body mass index, and comorbidities. HFrEF, heart failure with reduced ejection fraction (n = 400); HFbetterEF, heart failure with better ejection fraction (n = 382); HFpEF, heart failure with preserved ejection fraction (n = 166)